Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer
Endometrial cancer patients with advanced disease or high recurrence risk are treated with chemotherapy. Our objective was to evaluate the utility and mechanism of a novel drug, SHetA2, alone and in combination with paclitaxel, in endometrial cancer. SHetA2 targets the HSPA chaperone proteins, Grp78...
Main Authors: | Vishal Chandra, Rajani Rai, Doris Mangiaracina Benbrook |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/10/2322 |
Similar Items
-
Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2
by: Rajani Rai, et al.
Published: (2022-09-01) -
Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib
by: Amy L. Kennedy, et al.
Published: (2020-05-01) -
Ha in Sheta
by: Andrzej Ćwiek
Published: (2016-01-01) -
Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2.
by: Ankur Sharma, et al.
Published: (2018-01-01) -
Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane against Endometrial Cancer
by: Rajani Rai, et al.
Published: (2020-05-01)